[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"aphakia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:aphakia":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,44,66,87,106],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100630170","contralateral-claims-study-of-clareon-vivity-pro-100630170",false,"NCT07484191","Contralateral Claims Study of Clareon Vivity Pro","Key Inclusion Criteria:\n\n* Cataracts in both eyes.\n* Preoperative corneal astigmatism of less than 1.00 diopter (D) in each eye.\n* Potential postoperative best corrected visual acuity (BCDVA) of 0.2 logMAR or better in each eye in the expert medical opinion of the investigator.\n* Other protocol-defined inclusion criteria may apply.\n\nKey Exclusion Criteria:\n\n* Desires monovision correction.\n* Predicted post-operative residual astigmatism of more than 1D in either eye.\n* Any ocular or systemic co-morbidity that, in the investigator's medical opinion, may confound the results of this study, prohibit the completion of the study assessments, or increase the risk for the subject.\n* Other protocol-defined exclusion criteria may apply.","ALL","22 Years",{"count":18,"type":19},231,"ESTIMATED","INTERVENTIONAL",[22],"NA","The purpose of this study is to test new versions of Clareon Vivity Pro intraocular lenses (IOLs) by comparing them to currently marketed IOLs.",[25,26],"Aphakia","Presbyopia",[28,29,30],"Cataract","Eye Surgery","Intermediate Vision","RECRUITING","2026-06-11",{"date":34,"type":35},"2026-06-15","ACTUAL",{"date":37,"type":35},"2026-04-28",{"date":39,"type":19},"2027-02",{"name":41,"class":42},"Alcon Research","INDUSTRY",9,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":20,"phases":53,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":5},"100631574","clareon-truplus-study-100631574","NCT07502456","Clareon TruPlus Study","Clareon TruPlus Single-Arm Study","Key Inclusion Criteria:\n\n* Diagnosed with bilateral cataracts and planned bilateral cataract extraction by routine phacoemulsification.\n* Potential postoperative BCDVA of 0.2 logMAR or better in each eye in the expert medical opinion of the investigator.\n* Astigmatism suitable for correction with available toric IOL models.\n* Other protocol-specified inclusion criteria may apply.\n\nKey Exclusion Criteria:\n\n* Age-related macular degeneration (AMD), glaucoma, diabetic retinopathy, and other eye conditions as specified in the protocol.\n* Moderate to severe dry eye that would affect study measurements.\n* Other protocol-specified exclusion criteria may apply.",{"count":52,"type":19},122,[22],"The purpose of this research study is to generate safety and performance data for Clareon TruPlus Monofocal Intraocular Lenses (IOLs). IOLs are medical devices that are implanted in the eye during cataract surgery to restore clear vision after the cloudy natural lens has been removed. IOLs are intended to remain in the eyes for the duration of the patient's lifetime.",[25,56],"Astigmatism",[28],"2026-06-01",{"date":60,"type":35},"2026-06-03",{"date":62,"type":35},"2026-05-26",{"date":64,"type":19},"2028-06",{"name":41,"class":42},{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":72,"targetDuration":4,"studyType":20,"phases":74,"briefSummary":75,"conditions":76,"keywords":77,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},"100604259","feasibility-study-of-an-accommodating-iol-design-100604259","NCT07147192","Feasibility Study of an Accommodating IOL Design","Key Inclusion Criteria:\n\n* Able to understand and sign an Informed Consent Form.\n* Willing and able to attend all scheduled study visits required per protocol.\n* Diagnosed with bilateral cataracts requiring removal by phacoemulsification.\n* Preoperative corneal astigmatism equal to or less than 1.50 diopter (D) in both eyes.\n* Other protocol-defined inclusion criteria may apply.\n\nKey Exclusion Criteria:\n\n* Women of childbearing potential who are pregnant, intend to become pregnant during the study, or are breastfeeding.\n* Taking medications that could increase risk or may affect accommodation.\n* Eye conditions as specified in the protocol, including glaucoma or ocular hypertension.\n* Medical conditions that could increase operative risk as specified in the protocol.\n* Other protocol-defined exclusion criteria may apply.",{"count":73,"type":19},85,[22],"The purpose of this clinical study is to assess safety and explore usability and effectiveness of the test product, AAL-FAIOL. This study will be conducted in Central America.",[25],[28],"2026-05-18",{"date":80,"type":35},"2026-05-19",{"date":82,"type":35},"2025-12-03",{"date":84,"type":19},"2028-01",{"name":41,"class":42},4,{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":91,"acronym":4,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":93,"targetDuration":4,"studyType":20,"phases":95,"briefSummary":96,"conditions":97,"keywords":4,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":86},"100638560","clinical-evaluation-of-a-novel-trifocal-iol-100638560","NCT07587138","Clinical Evaluation of a Novel Trifocal IOL","Key Inclusion Criteria:\n\n* The calculated power needed for the artificial lens (IOL) must be between +15.0 and +25.0 D in each eye, designed to bring subject vision as close to \"0.0\" (neutral) as possible, meaning they will not be strongly nearsighted or farsighted after surgery.\n* Subjects must have low levels of astigmatism (misshapen cornea) in the eyes (less than 1.00 D).\n* In the doctor's opinion, the subjects have the potential to achieve good vision (0.2 logMAR, which is roughly 20\u002F32 Snellen or better) in each eye after the surgery, when wearing the best possible spectacles or contact lenses.\n* Other protocol-specified inclusion criteria may apply.\n\nKey Exclusion Criteria:\n\n* Clinically significant corneal diseases which may, according to the investigator's medical opinion, adversely affect visual outcomes.\n* Any ocular or systemic health condition or medical issue that, in the investigator's medical opinion, could make the study results unreliable, prevent the person from finishing the study, or increase their safety risk.\n* People who want to have one eye set for distance vision and the other for near vision.\n* The doctor expects significant blurry vision (astigmatism) after the procedure.\n* Other protocol-specified exclusion criteria may apply.",{"count":94,"type":19},66,[22],"The purpose of this study is to understand the visual outcomes of the investigational intraocular lens (IOL) Model LPYWT0 when compared to the commercially marketed Clareon PanOptix Pro IOL Model PXYWT0.",[25,28],"NOT_YET_RECRUITING","2026-05-14",{"date":78,"type":35},{"date":102,"type":19},"2026-10",{"date":104,"type":19},"2027-07",{"name":41,"class":42},{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":15,"minAge":114,"maxAge":4,"enrollmentInfo":115,"targetDuration":4,"studyType":20,"phases":117,"briefSummary":118,"conditions":119,"keywords":120,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":131},"100535967","bicentric-clinical-investigation-to-assess-safety-and-performance-of-luxboost-iol-100535967","NCT06258707","Bicentric Clinical Investigation to Assess Safety and Performance of LuxBoost IOL","Bicentric Clinical Investigation to Assess Safety and Performance of a Hydrophobic Acrylic Enhanced Monofocal Intraocular Lens.","LuxBoost","Inclusion Criteria:\n\n* Subject aged 50 or over on the day of inclusion, presenting a\n* bilateral cataract for which posterior chamber IOL implantation\n* has been planned.\n* Fit within the available IOL diopter range.\n* Have had no previous refractive surgery.\n* Regular corneal astigmatism \\\u003C 1 dioptre by an automatic\n* keratometer (regularity measured by topographer).\n* Availability, willingness, and sufficient cognitive awareness to\n* comply with examination procedures.\n* Ability to attend all study follow-ups.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Ocular surface disease potentially affecting study results\n* Subjects suffering from diagnosed degenerative visual disorders\n* Pre-existing ocular pathology\n* Acute or chronic disease or illness that would increase risk or confound study results\n* Axial lengths and keratometry such as the IOL spherical power is\n* not in the range of 14 to 28 D\n* Instability of keratometry or biometry measurements\n* Amblyopia\n* History of ocular trauma or any prior ocular surgery including refractive procedures\n* Capsular or zonular abnormalities that may affect postoperative centration or tilt of the lens","50 Years",{"count":116,"type":19},58,[22],"The study purpose is to demonstrate safety and performance of bilateral implantation of LuxBoost intraocular lenses compared with the LuxGood Monofocal lens.",[25],[121],"Enhanced monofocal IOL","2026-02-11",{"date":124,"type":35},"2026-02-12",{"date":126,"type":35},"2024-10-14",{"date":128,"type":19},"2027-06-15",{"name":130,"class":42},"Cutting Edge SAS",2]